Compare J B Hunt Transport Services Inc (JBHT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs TG Therapeutics Inc — how do they compare? J B Hunt Transport Services Inc trades at $290.65 (market cap $27.54B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: J B Hunt Transport Services Inc is far larger — about 3.3× TG Therapeutics Inc's market cap, and J B Hunt Transport Services Inc pays a 0.61% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| JBHT | TGTX | |
|---|---|---|
Market Cap | $27.54B | $8.26B |
Sector | Industrials | Health |
52-Week High | $298.41 | $59.06 |
52-Week Low | $130.65 | $26.39 |
Enterprise Value | $28.68B | $8.50B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
J.B. Hunt Transport Services (JBHT) trades at $293.26, up 0.63% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results featured EPS of $1.91 versus $1.71 expected, driven by intermodal growth and cost discipline. Revenue for 2025 was $12.00B with a net income margin of 4.98%. Analysts maintain a Buy consensus with a $299.82 price target, citing freight market recovery and margin expansion.
The outlook for JBHT is positive, supported by structural industry shifts toward rail and efficient network operations. Investment opportunities include continued earnings momentum and potential price appreciation toward the $345 high target. Risks involve premium valuation (P/E 41.45), economic sensitivity, and competitive pressures. The stock's current level demands careful valuation assessment despite favorable fundamentals and analyst optimism.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
